Psychiatric comorbidities and use of milnacipran in patients with chronic dizziness.
Psychiatric comorbidities and use of milnacipran in patients with chronic dizziness.
复制标题
慢性头晕患者的精神合并症和米那普仑的使用。
DOI：
10.3233/ves-160582
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
H. Inohara
中科院分区：
文献类型：
--
作者：
A. Horii;T. Imai;T. Kitahara;A. Uno;Y. Morita;Kuniyuki Takahashi;H. Inohara
背景
BACKGROUND
Psychiatric comorbidities are an important issue in the treatment of chronic dizziness patients.
OBJECTIVE
To test the correlation between psychiatric status and subjective handicaps and to examine the effects of milnacipran on handicaps.
METHODS
Hospital anxiety and depression scale (HADS) and handicaps were assessed by a questionnaire before and eight weeks after milnacipran treatment (50 mg/day) in 29 consecutive patients with chronic dizziness. Effects of milnaciplan were compared with fluvoxamine (200 mg/day).
RESULTS
A significant correlation was found between anxious and depressive scale scores and also between HADS and handicaps. Duration of symptoms was longer in the anxious/depressive group (HADS≧13) than in the non-anxious/depressive group. Handicaps and HADS were significantly decreased after treatment only in the anxious/depressive group. There were no overall differences in drug effects between milnaciplan and fluvoxamine. However, the rate of patients with a post/pre ratio of handicaps <80% was higher in milnaciplan group compared with the fluvoxamine group.
CONCLUSIONS
Not only anxiety disorders but also depression should be considered as comorbid psychiatric disorders in patients with chronic dizziness. Dizzy patients with psychiatric comorbidities have a longer duration of symptoms and more handicaps than those without psychiatric disorders. Milnacipran may be chosen as a treatment for patients with chronic dizziness with comorbid psychiatric disorders in case of and insufficient response to SSRIs.
米那普仑与三环类抗抑郁药的比较：对自杀患者的影响
影响因子：
3.2
作者：
Kirino E.;Gitoh M
通讯作者：
Gitoh M